Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies
Major Deal For ‘Gene Traffic Control’ Company
US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.
You may also be interested in...
Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold
The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.
Lilly Furthers Precision Cancer Ambitions With Foghorn Collaboration
Building on its Loxo Oncology unit, Lilly teams with Foghorn to target cancers caused by BRG1 mutations, about 5% of all tumors, including 10% of NSCLC patients. Merck & Co. teamed up with Foghorn in 2020.
Merck Pays $2.75bn To Access VelosBio’s ROR1-Targeting ADCs
Merck continues its cancer deal streak, purchasing a pipeline of antibody-drug conjugates and bispecific antibodies against receptor tyrosine kinase-like orphan receptor 1 (ROR1).